Management of Intracerebral Hemorrhage With Aminocaproic Acid - Pilot Study
Status:
Withdrawn
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This is single-arm, open-label, safety and feasibility pilot study of ɛ-aminocaproic acid in
ICH patients.
Consecutive ICH volume with hematoma volume less than 30 mL by ABC/2 method presenting within
3 hours of symptom onset, meeting all inclusion criteria, and without exclusions will be
consented and enrolled. Subjects will receive 5 grams of intravenous ɛ-aminocaproic acid over
1 hour, followed by the same at 1 mg/hour for 23 hours. Comupted tomography (CT) head will be
done at 24 hours in order to follow hematoma size. Electrocardiogram, lower extremity venous
Doppler and NIHSS will also be done at 24 hours. The patient will be followed in the clinic
30-90 days post discharge for functional status.
Phase:
Phase 1
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio